Injectable diabetes and weight-loss drugs (GLP-1 receptor agonists) can trigger pancreatitis and cysts.

Original statement

وأدوية السكري والتخسيس المحقونة قد تُحدث التهاب البنكرياس والأكياس.

not verbatim – paraphrase. Translation by the project; the Arabic wording is authoritative.

Translation

Injectable diabetes and weight-loss drugs (GLP-1 receptor agonists) can trigger pancreatitis and cysts.

Origin

Source status

Archive quote (no location given)

Attribution

Elawady (archive paraphrase; source video not given)

Origin

https://eltayebat.com/rule/oral-diabetes-drugs/

Attribution uncertainty

The archive attributes this text to Dr. Diaa in its 'د. ضياء يقول' box but gives no video reference. Transcript check (the project's research files, keyword search of 307 archive transcripts): found_close_paraphrase. GLP-1-based injectables ('gliptins', Mounjaro, Victoza) causing pancreatitis and a cyst 'stuck to the pancreas' are found in 0pG3-_Gr3eA.

Claimed health effect

Acute pancreatitis; cysts

Population concerned

Users of GLP-1 receptor agonists

Geographic restriction by Elawady

none found

Diverging source versions

Scientific assessment

Unclear / insufficient evidence – The data do not allow an assessment either way.

Certainty of evidence: low – Further research is likely to change the assessment considerably.

1. What was claimed?

GLP-1 injections cause pancreatitis and cysts.

2. What is demonstrably correct?

An administrative US case-control study found adjusted OR 2.24 for current GLP-1-based therapy use (A-ODD-14). Product labels warn about pancreatitis; ADA 2026 notes that 'acute pancreatitis has been reported, but causality has not been established' (I-ODD-16). GLP-1 receptor agonists frequently cause gastrointestinal adverse effects (A-ODD-15, I-ODD-07).

3. What is wrong or exaggerated?

A meta-analysis of three long-term blinded RCTs with adjudicated pancreatitis (9,347 vs 9,353 patients) found no increased risk (Peto OR 0.745) (I-ODD-11); in LEADER acute pancreatitis was not increased with liraglutide (18 vs 23 cases) (I-ODD-06); in SAVOR-TIMI (DPP-4 inhibitor) pancreatitis rates were similar (A-ODD-08). The case-control study had strong confounding: cases had far more gallstones, alcohol use, hypertriglyceridaemia and obesity (A-ODD-14). No evidence was found for 'cysts'; LEADER did not assess pancreatic cysts.

4. What remains unclear?

Whether a very small absolute increase in pancreatitis exists; trial sequential analysis suggested more evidence is needed (I-ODD-11). LEADER recorded more pancreatic carcinomas with liraglutide (13 vs 5; p=0.06) and more acute gallstone disease (3.1% vs 1.9%; p<0.001), a known cause of pancreatitis; the trial neither confirms nor excludes pancreatic neoplasia (I-ODD-06).

5. Which studies support it?

A-ODD-14.

6. Which studies contradict it?

I-ODD-11, A-ODD-08; I-ODD-06 (no excess acute pancreatitis).

7. What applies to Germany and Europe?

Same EU labelling.

8. What is known about Egypt?

GLP-1 RAs for weight loss are increasingly used, partly obtained without prescription; supervision is advisable.

9. What practical conclusion is appropriate?

Severe persistent abdominal pain on GLP-1 RA therapy needs medical evaluation; current evidence does not show a clear causal pancreatitis risk.

Assessment details

Rationale for certainty of evidence

Observational studies show associations (OR about 2 in a US claims case-control study), labels carry warnings, but meta-analysis of large blinded RCTs found no increase (Peto OR 0.745, 95% CI 0.47-1.17). 'Cysts' is not specified; no evidence was found linking GLP-1 RAs to pancreatic cysts. The word 'can' makes the claim weak; a rare effect cannot be ruled out.

Source quality

Archive paraphrase without video reference.

Regional transferability

Universal.

Individual exceptions

History of pancreatitis or gallstone disease increases baseline risk; rapid weight loss raises gallstone risk.

Regional scope of the claim

general (biological/medical)

Last reviewed

25 October 2026 provisional

In plain language

Some database studies suggested that GLP-1 injections might cause pancreas inflammation, but large randomised trials did not find more cases than with placebo. Doctors still warn patients to report severe stomach pain. There is no evidence that these drugs cause cysts.

Studies on this claim

Regional context

Germany / EU

Same EU labelling.

Egypt

GLP-1 RAs for weight loss are increasingly used, partly obtained without prescription; supervision is advisable.

What applies in my country?

General scientific assessment

Unclear / insufficient evidence A pancreatitis signal from observational data was not confirmed in large trials; 'cysts' is unsupported.

This statement concerns biological or medical relationships. The scientific assessment above applies regardless of the country; country-specific food data do not change it.

References

1. Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study.. Singh S et al.. JAMA Intern Med 2013 · PMID 23440284 · DOI 10.1001/jamainternmed.2013.2720
2. Glucagon-like peptide-1 receptor agonists and risk of acute pancreatitis in patients with type 2 diabetes.. Storgaard H et al.. Diabetes Obes Metab 2017 · PMID 28105738 · DOI 10.1111/dom.12885
3. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus.. Scirica BM et al.. N Engl J Med 2013 · PMID 23992601 · DOI 10.1056/NEJMoa1307684
4. Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss.. Sodhi M et al.. JAMA 2023 · PMID 37796527 · DOI 10.1001/jama.2023.19574
5. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2026.. American Diabetes Association Professional Practice Committee for Diabetes*. Diabetes Care 2026 · PMID 41358900 · DOI 10.2337/dc26-S009
6. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.. Marso SP et al.. N Engl J Med 2016 · PMID 27295427 · DOI 10.1056/NEJMoa1603827